

SanaMind

FASTASeq 300*

High-throughput sequencing platform

----Flexible-Rapid-Easy-to-use

*Unless otherwise informed, GeneMind sequencing platform and related sequencing reagents are not available in the USA, Canada, Australia, Japan, Singapore, Western Europe and Nordic countries yet.

Company Introduction



GeneMind Biosciences

Explore Life's Mysteries for Better Healthcare

Established in 2012, GeneMind Biosciences Co., Ltd. is headquartered in Luohu, Shenzhen, with more than 10,000 square meters of working space including R&D lab and GMP production line.

Specializing in the independent R&D and manufacturing of molecular diagnosis technology platform centered on sequencing system, GeneMind is committed to working with genetic testing service providers and life science research institutions to build an industrial ecosystem that serves human life and health.

Milestones



*Unless otherwise informed, GeneMind sequencing platform and related sequencing reagents are not available in the USA, Canada, Australia, Japan, Singapore, Western Europe and Nordic countries yet.

Product Introduction

FASTASeq 300* High-throughput Sequencer

FASTASeq 300* is a desktop sequencer focused on targeted sequencing, whole-genome low-depth sequencing, with innovative breakthroughs in sequencing chemistry, high-density flowcell, fluid design and base identification algorithms, bringing users more flexibility, more consistent data quality and faster delivery.





Core Technologies



System Specifications

Unit	Flow cell Type	Lane	Reads	Read Length	Output (Gb)	Q30	Error rate	Sequencing Time ² (h) index (8+8)
	FCL	2	50 M	SE100	5.0	≥90%		5.5
		Δ	125 M	SE75	9.4	≥90%		4.5
	FCIVI	7		PE75	18.8	≥90%		8.0
				PE150	37.5	≥90%		13.0
4		4	280 M	SE75	21.0	≥90%	≤1%	5.0
I	FCH^4			PE75	42.0	≥90%		9.5
				PE150	84.0	≥90%		16.0
		_		SE400	40.0	≥80%		33.0
	FCX	2	100M	PE300	60.0	≥85%		48.0
				SE75	37.5	≥90%		7.5
	FCP ⁴	4 4	500 M	PE75	75.0	≥90%		14.0
				PE150	150.0	≥90%		24.0

1. The number of reads and Q30 are based on sequencing using standard libraries; performance may vary depending on library type and quality, insert size, loading concentration, and other experimental factors.

2.Sequencing time includes the time from sample loading to base identification to generate the Basefile file.

3. The sequencing accuracy is obtained by comparing the sequencing data with the reference genome ATCC8739.

4.FCM/FCH/FCP are the performance parameters of the sequencing kit V3.0.

Anglissting	Deed langth	Dete (comple	FCL	FCX	FCM	FCH	FCP
Application	kead length	Data/sample	50M	100M	125M	280M	500M
NIPT/PGT-A/CNV-Seq	SE75	5 M reads/sample	8	/	20	48	96
Small tumor panel (tissue)	PE75	0.2 Gb/sample	/	/	>96	>192	>382
Small tumor panel (ctDNA)	PE150	5 Gb/sample	/	/	6	16	32
Large tumor panel (tissue)	PE150	5-10 Gb/sample	/	/	3	8	16
mNGS	SE75	20 M reads/sample	2	/	4	12	24
tpNGS	PE150	0.1-1 M reads/sample	42	/	>96	>192	>384
16S/18S/ITS	PE300	0.1-0.2 M reads/sample	/	400	/	/	/
Forensic	SE400	1-2 M reads/sample	/	40	/	/	/

Recommended data output and sample numbers are only for reference, actual application will require optimisation adjustments.

Application summary



A total of 60 runs were counted (FASTASeq 300* FCH)

Parameter	Mean
Q30	90%
Output reads	310 M

Application—PGT-A/CNV-Seq/NIPT

- Sequencing:FASTASeq 300* Chromosomal Abnormality Detection
- Sample type:Construct PGT-A and CNV-seq libraries based on PGT-A reference standard and CNV-seq reference standard
- Read length:SE75

Table 1. Consistency assessment of CNV-Seq results

Table 2. Consistency assessment of PGT-A results

	CNV-Seq Reference Standard Sequencing											PGT-	A Referer	nce Stand	ard Sequencing		
No.	Sample	Effective data (reads)	Average GC	Average coverag	Average depth	Results	Reference standard	Consistency	No.	Sample	Effective data (reads)	Average GC	Average coverage	Average depth	Results	Reference standard	Consistency
1	GM12	4811803	38.15%	7.34%	0.159	+13	T13	Yes	1	GM02008	4641367	39.59%	5.92%	0.169	-11(q23.3-q25,~ 14.7Mb)	-11(q23.3-q25,~ 14.7Mb)	Yes
2	GM15	5187339	38.46%	7.88%	0.173	+16	T16	Yes	2	GM06473	5123946	39.33%	6.70%	0.183	-1(q43-q44,~ 9.9Mb)	-1(q43-q44,~ 9.9Mb)	Yes
3	GM21	5394891	38.26%	8.18%	0.178	-X	ХО	Yes	3	GM06097	4964662	39.43%	6.72%	0.179	-17(p13.3-p13.2,~ 4.2Mb)	-17(p13.3-p13.2,~ 4.2Mb)	Yes
4	GM27	5302386	38.18%	8.05%	0.177	-22 (q11.21,~ 2.96Mb)	22q11.21 (del,2.5Mb)	Yes	4	GM13325	5330814	39.49%	7.79%	0.197	-22(q11.21,~ 2.3Mb)	-22(q11.21,~ 2.3Mb)	Yes
5	GM31	4843680	38.50%	7.39%	0.162	-7 (q11.23, ~ 1.78Mb)	7q11.23 (del,1.8Mb)	Yes	5	GM25372	4115286	39.39%	5.42%	0.151	-17(p11.2,~ 1.2Mb)	-17(p11.2,~ 1.2Mb)	Yes
6	GM40	5845360	38.06%	8.82%	0.192	+X—31%; -1 (p36.33- p36.22,~ 10.65Mb)—31%	XXY—30%; 1p36.33-p36.22 (del,11.0Mb)—30%	Yes	6	GM01359	3914767	40.17%	5.84%	0.151	+18	+18	Yes
7	GM42	4906427	38.23%	7.48%	0.162	Normal	Regular Sample	Yes	7	GM02767	3872356	39.47%	5.08%	0.141	+21	+21	Yes

Conclusion:

FASTASeq 300* has excellent detection of chromosomal abnormalities.

Application-Target tumor panel

- Sample typr:HD832 (FFPE)
- Library prep:TruSight Oncology 500
- Sequencing platform:GenoLab M*, FASTASeq 300*,Competitor A (NS platform) and Competitor B (NV platform)
- Read length:PE150
- Analysis:Extract 100M reads/sample to do deep analysis

Platform	FATSASeq 300*	GenoLab M*	NS Platform	NV Platform	AF	Mut Number	FASTASeq 300*	GenoLab M*	NS Platform	NV Platform
Q30	91.33%	88.58%	83.45%	91.25%	AF≤10%	9	88.89%	77.78%	77.78%	77.78%
Total SE reads (M)	100	100	100	100	10% <af≤20%< td=""><td>24</td><td>100.00%</td><td>100.00%</td><td>100.00%</td><td>100.00%</td></af≤20%<>	24	100.00%	100.00%	100.00%	100.00%
Fold80	1.41	1.43	1.41	1.56	20% <af≤30%< td=""><td>49</td><td>100.00%</td><td>100.00%</td><td>100.00%</td><td>100.00%</td></af≤30%<>	49	100.00%	100.00%	100.00%	100.00%
Unique mapping rate	99.34%	99.22%	97.45%	98.14%	AF>30%	124	100.00%	100.00%	100.00%	100.00%
Target region rate	84.74%	84.37%	83.74%	83.05%	NGS no value	6	83.33%	83.33%	83.33%	83.33%
Target mean depth	1182	1551	1178	1165	Total	212	99.06%	98.58%	98.58%	98.58%

TAT: 24h (FASTASeq 300* FCH PE150 Dual index)

Conclusion:

High data quality (Q30>91%, unique mapping rate>99%) for FASTASeq 300*, the sequencing time only takes 24h for PE150. And the results of FASTASeq 300* mutation detection are consistent with GenoLab M and other competitors.

Targeted tumor panel

- ► Sample typr:HD832 (FFPE)
- Library prep:TruSight Oncology 500
- Sequencing platform:GenoLab M*, FASTASeq 300*, Competitor A and Competitor B
- ► Read length:PE150
- Analysis:Extract 100M reads/sample to do deep analysis

AF	Mut Number	FASTASeq 300*	GenoLab M*	NS□Platform	NV□Platform	100% CB platform r=0.99
AF≤10%	9	88.89%	77.78%	77.78%	77.78%	75% 75% 50% 50%
10% <af≤20%< th=""><th>24</th><th>100.00%</th><th>100.00%</th><th>100.00%</th><th>100.00%</th><th>25% 25% 25%</th></af≤20%<>	24	100.00%	100.00%	100.00%	100.00%	25% 25% 25%
20% <af≤30%< th=""><th>49</th><th>100.00%</th><th>100.00%</th><th>100.00%</th><th>100.00%</th><th>0% 0% 25% 50% 75% 100% 0% 25% 50% 75% 10 100% 0% 25% 50% 75% 100% 0% 25% 50% 75% 10</th></af≤30%<>	49	100.00%	100.00%	100.00%	100.00%	0% 0% 25% 50% 75% 100% 0% 25% 50% 75% 10 100% 0% 25% 50% 75% 100% 0% 25% 50% 75% 10
AF>30%	124	100.00%	100.00%	100.00%	100.00%	
NGS no value	6	83.33%	83.33%	83.33%	83.33%	50% 50% 25% 25%
Total	212	99.06%	98.58%	98.58%	98.58%	0% 25% 50% 75% 100% 0% 25% 50% 75% 11

Conclusion:

The results of FASTASeq 300* mutation detection are consistent with GenoLab M and other competitors.

Application-mNGS

- sample type:Clinical samples(Alveolar lavage fluid, sanies, urine, tissue, hydrothorax)
- Library:6 mNGS libaries
- Sequencing platfirm:GenoLab M*, FASTASeq 300*
- ► Read length:SE50
- Data analysis:50M reads/sample for deep anaysis



Conclusion:

The microbial detection of FASTASeq 300* are consistent with GenoLab M, and the clinical judgment results of all test samples are 100% accurate detected.

Application- De novo WGS (single bacteria assembling)

- Sample type:Using Legionella pneumophila subsp. Pneumophila construct WGS library
- Sequencing platform:FASTASeq 300*, GenoLab M*, Competitor A(CA)
- ► Read length:PE150

	Assembling results							
Platform	FASTASeq 300*	GenoLab M*	CA					
Q30	92.10%	91.93%	90.60%					
Total Length (bp)	3387746	3376652	3377221					
Reference Length (bp)	3409194	3409194	3409194					
Genome Fraction	99.02%	99.02%	99.04%					
GC Content	38.22%	38.23%	38.23%					
Reference GC Content	38.33%	38.33%	38.33%					
Contigs	28	27	29					
Largest Contig (bp)	989763	989763	989763					
Contig N50 (bp)	363258	363258	363482					



TAT: 19.5h (FASTASeq 300* FCM PE150 0 index)

Conclusion:

Data quality and assembling results are quite comparable with GenoLab M* and CA, the sequencing time only takes 19.5h for PE150.

Application-WES

- Sample type:HG001(NA12878), HG002(NA24835)
- Library prep:Agilent SureSelect Human All Exon V6
- Sequencing Platform:FASTASeq 300*,GenoLab M*, Competitor A(NV platform)
- Read length:PE150
- Analysis:12Gb/sample for deep analysis

Platform		HG001-WES			HG002-WES	
Flationin	FASTASeq 300*	GenoLab M*	Competitor A	FASTASeq 300*	GenoLab M*	Competitor A
Raw data (Gb)	12	12	12	12	12	12
Clean data (Gb)	11.99	11.99	11.95	11.99	11.99	11.96
Properly paired reads	99.49%	99.62%	98.81%	99.60%	99.65%	98.92%
Capture efficiency	77.91%	77.93%	78.29%	78.78%	78.49%	78.91%
Mean sequencing depth	124.59	124.64	124.78	125.95	125.75	126.05
Duplication ratio	3.46%	5.48%	21.03%	5.79%	5.22%	19.60%
Coverage at lease 0×	99.64%	99.64%	99.65%	99.87%	99.87%	99.85%
Coverage at lease 4×	99.52%	99.52%	99.55%	99.65%	99.67%	99.56%
Coverage at lease 10×	99.06%	99.05%	99.19%	98.57%	98.68%	98.16%
Coverage at lease 30×	94.95%	95.16%	94.67%	89.56%	90.32%	87.33%



Conclusion: High data quality(Q30>91%, low duplication rate<5%)

Conclusion: FASTASeq 300* excels in sensitivity and precision for germline mutation (SNV and InDel) detection.

Application-16S rDNA

- Sample type: ZymoBIOMICS Microbial Community DNA Standard
- Library prep: Zymo_16S_1、Zymo_16S_2、Zymo_16S_3
- Sequencing platform: FASTASeq 300*, Competitor N
- Read length: PE300
- Data analysis: extract 0.1M reads/sample for deep analysis

Raw Q30%	Zymo_16S_1	Zymo_16S_2	Zymo_16S_3
FASTASeq 300*_1	90.57%	90.14%	89.54%
FASTASeq 300*_2	89.70%	89.39%	90.24%
Competitor	84.55%	84.78%	84.62%





Intellectual Property & Qualifications



Sequencing systems are multidisciplinary specialities that combine optics, fluids, algorithms, chemistry and molecular biology. Since its establishment, GeneMind has been specializing in the independent R&D and manufacturing of molecular diagnosis technology platform centered on sequencing system. We have continuously innovated and accumulated a lot of intellectual property rights in the underlying technologies such as instrument hardware, reagent, flowcell and software algorithms.

As of April 2024, GeneMind has more than 5 00 granted domestic and foreign patents, and has successfully obtained ISO 13485 medical device quality management system certification. The sequencer, reagent kits and other products have also received CE certification, NMPA medical device approval.











Independent Research & Development

In addition to the innovative breakthroughs in sequencer development, GeneMind has also realized the independent R&D and production of core materials such as enzymes, nucleotide analogues, fluorochrome and flowcell. The company has the ability to develop and manufacture the total solution of "instrument-reagent-flow cell-software" independently, and are able to provide customers total solution with good quality, low cost and short delivery time.

The total area of R&D and production in use is nearly 10,000 square meters, with sequencer production factory, GMP reagent kit production line, flow cell laboratory, organic synthesis laboratory and enzyme engineering laboratory. The designed annual capacity of sequencer is 1000 units and the annual capacity of kits is 2.4 million tests.



 Sequencer Production Line Designed with annual production capacity of 1000 seq Flow cell Lab
In-house production of sequencing

Organic Synthesis Lab
Able to synthesize our own nucleic acid and fluorochrome



Reagent Kits Production Line
Designed as a GMP workshop to produce kits for 2.4 million tests annually

• Enzyme Engineering Lab Independent research and development of core enzyme

Partners





Product Information

Product Type	PN	Product Name	Module/Specification
Sequencer	SQ00020	FASTASeq 300 sequencing system	RUO
	S000447	FASTASeq 300 Sequencing Kit V3.0 (FCM-D SE075-D)	FCM-D SE075-D
	S000448	FASTASeq 300 Sequencing Kit V3.0 (FCM 150cycles)	FCM 150cycles
	S000449	FASTASeq 300 Sequencing Kit V3.0 (FCM 300cycles)	FCM 300cycles
	S000450	FASTASeq 300 Sequencing Kit V3.0 (FCH-D SE075-D)	FCH-D SE075-D
	S000451	FASTASeq 300 Sequencing Kit V3.0 (FCH 150cycles)	FCH 150cycles
Descents	S000452	FASTASeq 300 Sequencing Kit V3.0 (FCH 300cycles)	FCH 300cycles
Reagents	S000453	FASTASeq 300 Sequencing Kit V3.0 (FCP-D SE075-D)	FCP-D SE075-D
	S000454	FASTASeq 300 Sequencing Kit V3.0 (FCP 150cycles)	FCP 150cycles
	S000455	FASTASeq 300 Sequencing Kit V3.0 (FCP 300cycles)	FCP 300cycles
	S000290	FASTASeq 300 Sequencing Kit V2.0 (FCL-D SE100-D)	FCL-D SE100-D
	S000406	FASTASeq 300 Sequencing Kit V2.0 (FCX 400cycles)	FCX 400cycles
	S000277	FASTASeq 300 Sequencing Kit V2.0 (FCX 600cycles)	FCX 600cycles

	Specification
Dimensions	684 mm × 644 mm × 615 mm
Weight	145 kg
Power	2000 VA
Power Requirement	100-240 V~, 50/60 Hz
Operating Environment	Temperature:19°C-25°C Humidity: 20%-80% relative humidity (no-condensing) Altitude: below 3000 meter
Computer	CPU: Intel Xeon Silver 4216 Memory: 32 GB DDR4*6 Hard Drive 1: 480 Gb Hard Drive 2: 2 TB HDD System: Windows10 x64



GeneMind Biosciences Co., Ltd.

Technical support hotline: +86-400-822-3660 Website: en.genemind.com Email: info@genemind.com Address: Room 502A/502B/602, Luohu Investment Holding Building, 112 Qingshuihe 1st Road, Luohu District, Shenzhen, Guangdong, China

